Huberman LabDr. David Fajgenbaum on Huberman Lab: How Old Drugs Cure
Fajgenbaum survived Castleman disease on a repurposed drug from his local pharmacy; now AI is scanning all FDA-approved generics for overlooked cancer cures.
CHAPTERS
- 0:00 – 7:00
A System Blind Spot: Old Drugs, Untapped Cures
Fajgenbaum opens with the moment his doctor told him there were no options left, prompting his realization that the medical system had only tried a tiny fraction of existing drugs for his disease. Huberman frames the episode’s central thesis: many effective treatments or even cures already exist but remain unknown or unused because of how drugs are studied, patented, and categorized.
- 7:00 – 27:00
Existing Drugs, Hidden Uses: Aspirin, Viagra, Lidocaine & More
The discussion moves into concrete examples of drugs whose lesser-known benefits could be saving more lives. They explore how the economics of generics and patents, not just scientific evidence, determine whether secondary uses like aspirin in colon cancer or lidocaine in breast surgery become standard of care.
- 27:00 – 44:00
Patents, Profits, and Why Repurposing Stalls
Huberman and Fajgenbaum dissect how the patent system drives pharma behavior and leaves most repurposing opportunities on the table. They distinguish between formulation tweaks to extend a patent in the same disease versus genuine new indications and highlight the 14,000 diseases with no approved treatment at all.
- 44:00 – 59:00
How to Self‑Advocate: Disease Groups, Experts, and Questions
They outline practical strategies for ordinary people to find cutting-edge options without medical training. Case studies like the TNF inhibitor for DADA2 illustrate how a single clinician’s observation remained siloed for years until a motivated parent and collaborators turned it into guidelines that now save children globally.
- 59:00 – 1:20:00
Repurposed Drug Wins: Thalidomide, Pembrolizumab, Colchicine
Fajgenbaum walks through notable successes where drugs found second or third lives in seemingly unrelated diseases. These stories underscore how often the key evidence already exists in the literature but hasn’t been translated into practice, and how little brilliance is sometimes required beyond connecting the dots.
- 1:20:00 – 1:43:00
From Supplements to Statins: Rethinking ‘Natural’ vs. ‘Pharma’
Huberman and Fajgenbaum blur the line between natural substances and drugs, pointing out that many prescriptions originate from plants, microbes, or soil. They discuss examples like rapamycin from Easter Island soil, kratom, coca, and Mucuna pruriens, arguing that the key issue is not natural vs. synthetic but evidence, dosing, and control.
- 1:43:00 – 1:58:00
David’s Origin Story: Losing His Mother, Football, and Medicine
Fajgenbaum shares how his mother’s fatal glioblastoma shifted him from a football-obsessed teen to a mission-driven future physician. Her resilience and humor in the face of brain surgery, captured in her ‘Chiquita banana lady’ joke post‑op, became a template for how to reclaim agency and dignity amid severe illness.
- 1:58:00 – 2:21:00
Castleman Disease: From Healthy Med Student to Multi‑Organ Failure
He recounts his abrupt collapse from healthy, high-performing medical student and athlete into a critically ill ICU patient with multi‑organ failure. Misdiagnosed as lymphoma or autoimmune disease, he endures months of transfusions, dialysis, and 100 pounds of fluid overload before finally getting a Castleman disease diagnosis and a temporary reprieve from combination chemotherapy.
- 2:21:00 – 2:35:00
The ‘Santa Claus Theory’ of Medicine and Its Collapse
Huberman and Fajgenbaum examine the naive belief that somewhere there is a coordinated workshop of experts solving every medical problem as fast as possible. David’s experience—learning that a Castleman drug existed in Japan yet was unknown to his US team—shatters this illusion and highlights the randomness and fragmentation of real‑world biomedical progress.
- 2:35:00 – 2:54:00
Almost Dying Five Times and Discovering Rapamycin
After multiple near-fatal relapses and being told there is nothing left to try, Fajgenbaum decides to become his own scientist. He collects his own samples, learns lab methods, and eventually identifies hyperactivation of the mTOR pathway in his tissues, leading him to propose high‑dose sirolimus—an organ transplant drug—as a therapy. It becomes his long-term lifeline.
- 2:54:00 – 3:17:00
From Personal Cure to Global Mission: Lab, Every Cure, and AI
With his own disease controlled by sirolimus, Fajgenbaum formalizes his approach: he completes business school to learn systems and incentives, founds a research lab at Penn, and co-founds Every Cure. They use AI and knowledge graphs to systematically generate and rank all plausible drug–disease matches and then validate the top candidates experimentally and clinically.
- 3:17:00 – 3:36:00
Balancing Innovation With Safety: Off‑Label Use and Risk
They confront the ethical and practical risk of trying drugs off‑label in desperate situations. While N-of-1 repurposing has saved lives, a single catastrophic outcome could chill entire fields—as happened historically with gene therapy or contaminated supplements—so Every Cure emphasizes rigorous evidence synthesis, clear communication, and physician-driven decisions.
- 3:36:00 – 4:01:00
Hope, Tenacity, and the Neuroscience of ‘Overtime’
The conversation turns inward as Fajgenbaum describes the psychological tools that sustained him—living in ‘overtime’, breaking suffering into one-more-breath or one-more-day increments, and drawing strength from family. Huberman maps this onto specific brain circuitry, especially the anterior mid‑cingulate cortex, which appears central to perseverance and the will to live.
- 4:01:00
How to Engage With Every Cure and the Path Forward
In closing, they discuss how clinicians, patients, and the public can support and participate in Every Cure’s work. With substantial government and philanthropic backing already in place, the project aims to translate AI-identified matches into lab validation, trials, guidelines, and ultimately a world where no one dies simply because a cheap, existing drug wasn’t tried.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome